Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Cell Biol ; 36(3): 462-74, 2016 02 01.
Article in English | MEDLINE | ID: mdl-26598605

ABSTRACT

The class I histone deacetylases (HDACs) HDAC1 and HDAC2 play partially redundant roles in the regulation of gene expression and mouse development. As part of multisubunit corepressor complexes, these two deacetylases exhibit both enzymatic and nonenzymatic functions. To examine the impact of the catalytic activities of HDAC1 and HDAC2, we generated knock-in mice expressing catalytically inactive isoforms, which are still incorporated into the HDAC1/HDAC2 corepressor complexes. Surprisingly, heterozygous mice expressing catalytically inactive HDAC2 die within a few hours after birth, while heterozygous HDAC1 mutant mice are indistinguishable from wild-type littermates. Heterozygous HDAC2 mutant mice show an unaltered composition but reduced associated deacetylase activity of corepressor complexes and exhibit a more severe phenotype than HDAC2-null mice. They display changes in brain architecture accompanied by premature expression of the key regulator protein kinase C delta. Our study reveals a dominant negative effect of catalytically inactive HDAC2 on specific corepressor complexes resulting in histone hyperacetylation, transcriptional derepression, and, ultimately, perinatal lethality.


Subject(s)
Histone Deacetylase 2/genetics , Histone Deacetylase 2/metabolism , Mice/growth & development , Animals , Female , Gene Deletion , Gene Expression , Gene Knock-In Techniques , Histone Deacetylase 1/genetics , Histone Deacetylase 1/metabolism , Male , Mice/genetics , Mice/metabolism , Mice, Inbred C57BL , Mutagenesis, Site-Directed , Phenotype , Point Mutation , Transcriptional Activation
2.
Handb Exp Pharmacol ; 206: 13-37, 2011.
Article in English | MEDLINE | ID: mdl-21879444

ABSTRACT

Traditionally, cancer has been regarded to originate from genetic alterations such as mutations, deletions, rearrangements as well as gene amplifications, leading to abnormal expression of tumor suppressor genes and oncogenes. An increasing body of evidence indicates that in addition to changes in DNA sequence, epigenetic alterations contribute to cancer initiation and progression. In contrast to genetic mutations, epigenetic changes are reversible and therefore an attractive target for cancer therapy. Many epi-drugs such as histone deacetylase (HDAC) inhibitors showed anticancer activity in cell culture and animal models of carcinogenesis. Recently, the two HDAC inhibitors suberoylanilide hydroxamic acid (SAHA, Vorinostat) and Romidepsin (Depsipeptide, FK228) were FDA approved for the treatment of cutaneous T-cell lymphoma (CTCL). Although HDAC inhibitors are potent anticancer agents, these compounds act against several HDAC family members potentially resulting in numerous side effects. This stems from the fact that HDACs play crucial roles in a variety of biological processes including cell cycle progression, proliferation, differentiation, and development. Consistently, mice deficient in single HDACs mostly exhibit severe phenotypes. Therefore, it is necessary to specify the cancer-relevant HDACs in a given tumor type in order to design selective inhibitors that target only cancer cells without affecting normal cells. In this chapter, we summarize the current state of knowledge of individual nuclear HDAC family members in development and tumorigenesis, their contribution to the hallmarks of cancer, and the involvement of HDAC family members in different types of human malignancies.


Subject(s)
Cell Nucleus/enzymology , Epigenesis, Genetic , Histone Deacetylases/metabolism , Neoplasms/enzymology , Animals , Antineoplastic Agents/therapeutic use , Cell Nucleus/drug effects , Epigenesis, Genetic/drug effects , Gene Expression Regulation, Neoplastic , Histone Deacetylase Inhibitors/therapeutic use , Histone Deacetylases/genetics , Humans , Neoplasms/drug therapy , Neoplasms/genetics , Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...